GTCR already owns the second largest medical device coatings manufacturer, Biocoat, and the FTC holds market monopoly ...

Surmodics, Inc. (Nasdaq: SRDX), a provider of medical device and in vitro diagnostic technologies to the healthcare industry, ...

The agency is challenging the deal, citing antitrust concerns due to GTCR's existing ownership of Surmodics' rival Biocoat.

Surmodics stock drops 4.76% in premarket trading following news that the FTC will challenge its proposed acquisition by GTCR.

The Federal Trade Commission sued Thursday to block private equity firm GTCR BC Holdings’ acquisition of Surmodics Inc., ...

The regulator says the proposed merger would give the combined company more than 50% of the market for a type of medical ...

The Federal Trade Commission on March 6 sued to block GTCR’ s acquisition of Surmodics, alleging that “the deal, which seeks to combine the two largest manufacturers of critical medical device ...

Additional Information About the Pending Acquisition of Surmodics by funds affiliated with GTCR On May 29, 2024, Surmodics announced it had entered into a definitive merger agreement to be ...

The U.S. Federal Trade Commission (FTC) has filed a lawsuit to prevent medical device coatings maker Surmodics from merging ...

The FTC said merging Surmodics with Biocoat, where GTCR has a majority stake, would result in one company with more than 50% ...

FTC files lawsuit to block Surmodics' $627M GTCR sale. Learn about the implications of this decision and its impact on SRDX.